Coya Therapeutics (Coya Therapeutics) Ending Cash Position : $35.99 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics Ending Cash Position?

Coya Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was $35.99 Mil.

Coya Therapeutics's quarterly Ending Cash Position increased from Sep. 2023 ($10.89 Mil) to Dec. 2023 ($32.63 Mil) and increased from Dec. 2023 ($32.63 Mil) to Mar. 2024 ($35.99 Mil).

Coya Therapeutics's annual Ending Cash Position increased from Dec. 2021 ($4.34 Mil) to Dec. 2022 ($5.93 Mil) and increased from Dec. 2022 ($5.93 Mil) to Dec. 2023 ($32.63 Mil).

Coya Therapeutics Ending Cash Position Historical Data

The historical data trend for Coya Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics Ending Cash Position Chart

Coya Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

4.34

5.93

32.63

Coya Therapeutics Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial						16.32	13.10	10.89	32.63	35.99

Coya Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Coya Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	5.934	+	26.693
	=	32.63

Coya Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	32.626	+	3.363
	=	35.99

Coya Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Coya Therapeutics (Coya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057

Website

https://www.coyatherapeutics.com

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Executives

Dieter Weinand	director	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Fred Grossman	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Goldstein Dov A Md	director
Adrian Hepner	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
David S Snyder	officer: Chief Financial Officer	ONE SCIENCE COURT, MADISON WI 53711
Hideki Garren	director	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman	director, 10 percent owner, officer: Chief Executive Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc	10 percent owner	5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057